Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

(RTTNews) - AbbVie (ABBV) has completed its acquisition of Capstan Therapeutics, bringing the biotech company under its umbrella. Capstan's lead program, CPTX2309, is a Phase 1 tLNP-based therapy that ...

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...

NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, ...

AbbVie will pay US$2.1 billion to acquire Capstan Therapeutics and its in vivo CAR T technology, which uses mRNA-loaded lipid nanoparticles (LNPs) to reprogramme immune cells. Capstan’s lead asset is ...

Capstan Therapeutics — a biotechnology company pioneered by Penn researchers — was acquired by AbbVie in $2.1 billion deal. Capstan, which specializes in CAR-T therapies for autoimmune disorders, ...

Normally when you hear the words “rope” and “dog” in the same sentence, you think about a dog on a leash, but in this robot dog, the rope is what makes it move, not what stops it from going too far.

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up ...